In a year that surprised skeptics, China equities delivered strong performance in 2025, buoyed by improving corporate fundamentals, strengthening earnings and policy reforms.

For Reuters Pharma Europe 2025, pharmaphorum is providing coverage courtesy NAVLIN Daily, a pricing and market access insights report from EVERSANA (pharmaphorum's parent company). You can see the ...

CEO John Hall reported "strong quarterly results, supported by the addition of new clients and the expansion of client accounts around the world." He emphasized that "Cloud ARR grew to $434 million, ...